Harmony Biosciences
HRMY
39.34
-0.02
-0.05%
Harmony Biosciences
US · HRMY
#2681 by market cap
Listed 2020
39.34
-0.02
-0.05%
Live - 5344 symbols - heartbeat 88s ago
· 2026-10-08 07:30
Pre-market
39.95
+1.55%
After-hours
39.25
-0.23%
Overnight
38.91
-1.09%
- Market cap
- 2.29B
- P/E (TTM)i
- 12.73
- P/Bi
- 2.29
- EPSi
- 2.71
- Div yieldi
- 0.00%
- 52W posi
- 77%
Reader sentiment
Are you bullish or bearish on HRMY?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 7 analysts
Buy
Avg price target
46.43 +18.0%
Price target rangecurrent 39.34
Low30.00
Avg46.43
High60.00
Buy 57%
Hold 29%
Sell 14%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-01 | Deutsche Bank | -- | HOLD | 42.00 |
| 2026-09-25 | Mizuho Securities | -- | BUY | 51.00 |
| 2026-09-24 | Needham | -- | BUY | 50.00 |
| 2026-08-26 | Wolfe Research | -- | BUY | 60.00 |
| 2026-08-12 | H.C. Wainwright | -- | BUY | 55.00 |
| 2026-08-05 | Mizuho Securities | -- | BUY | 51.00 |
| 2026-08-05 | Deutsche Bank | -- | HOLD | 39.00 |
| 2026-08-04 | Mizuho Securities | -- | BUY | 51.00 |
| 2026-08-04 | BofA Securities | -- | SELL | 30.00 |
| 2026-08-04 | Needham | -- | BUY | 50.00 |
| 2026-08-04 | H.C. Wainwright | -- | BUY | 55.00 |
| 2026-07-31 | Mizuho Securities | -- | BUY | 51.00 |
| 2026-07-27 | Mizuho Securities | -- | BUY | 50.00 |
| 2026-07-20 | H.C. Wainwright | -- | BUY | 55.00 |
| 2026-07-16 | Mizuho Securities | -- | BUY | 50.00 |
| 2026-07-16 | Needham | -- | BUY | 45.00 |
| 2026-07-16 | Goldman Sachs | -- | HOLD | 37.00 |
| 2026-07-16 | H.C. Wainwright | -- | BUY | 55.00 |
| 2026-07-08 | Mizuho Securities | -- | BUY | 50.00 |
| 2026-06-30 | Deutsche Bank | -- | HOLD | 36.00 |
| 2026-06-23 | H.C. Wainwright | -- | BUY | 55.00 |
| 2026-06-11 | Mizuho Securities | -- | BUY | 50.00 |
| 2026-05-22 | H.C. Wainwright | -- | BUY | 55.00 |
| 2026-05-13 | Mizuho Securities | -- | BUY | 50.00 |
| 2026-05-12 | H.C. Wainwright | -- | BUY | 55.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
2
■ Upgrades■ Downgrades
- 0 upgrades vs 2 downgrades among tracked analyst rating changes.
- Most recent: UBS moved from Buy to Hold on 2026-02-20.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-02-20 | UBS | BUY → HOLD | 46.00 |
| 2026-02-19 | Truist Financial | BUY → HOLD | -- |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-04 | -- | ±16.79% | +8.93% (in line) |
| 2026/Q1 | 2026-05-07 | -- | ±14.03% | -4.15% (in line) |
| 2025/Q4 | 2026-02-24 | -- | ±14.00% | +4.91% (in line) |
| 2025/Q3 | 2025-11-04 | -- | ±11.00% | +4.74% (in line) |
| 2025/Q2 | 2025-08-05 | -- | ±17.96% | -1.69% (in line) |
| 2025/Q1 | 2025-05-06 | -- | ±13.45% | +6.98% (in line) |
| 2024/Q4 | 2025-02-25 | -- | ±13.47% | +8.16% (in line) |
| 2024/Q3 | 2024-10-29 | -- | ±16.69% | +16.06% (in line) |
| 2024/Q2 | 2024-08-06 | -- | ±23.30% | +6.18% (in line) |
| 2024/Q1 | 2024-04-30 | -- | ±13.46% | +5.68% (in line) |
| 2023/Q4 | 2024-02-22 | -- | ±17.42% | -4.70% (in line) |
| 2023/Q3 | 2023-10-31 | -- | ±14.71% | +19.43% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:30:11 · For reference only, not investment advice and not tailored to your situation.